To meet responder criteria, patients had to:
FOCUS=Ceftaroline Community-Acquired Pneumonia Trial vs Ceftriaxone in Hospital Patients. FOCUS 1=CABP Trial 1, FOCUS 2=CABP Trial 2.
Clinical efficacy of TEFLARO in treating CABP due to MRSA has not been studied.
Proven response against the most common pathogens in CABP7 | ||
Integrated FOCUS Day 4 data, % (n/N) | ||
Pathogen | TEFLARO | Ceftriaxone |
Gram-positive | ||
S. pneumoniae | 73.0 (54/74) | 56.0 (42/75) |
S. aureus (MSSA only†) | 58.3 (14/24) | 54.8 (17/31) |
Gram-negative | ||
H. influenzae | 76.2 (16/21) | 71.4 (20/28) |
K. pneumoniae | 77.8 (14/18) | 58.3 (7/12) |
K. oxytoca | 100.0 (6/6) | 100.0 (6/6) |
E. coli | 33.3 (4/12) | 53.8 (7/13) |
Proven response against the most common pathogens in CABP7 | |
Integrated FOCUS Day 4 data, % (n/N) |
|
TEFLARO | Ceftriaxone |
Pathogen | |
Gram-positive | |
S. pneumoniae | |
73.0 (54/74) | 56.0 (42/75) |
S. aureus (MSSA only†) | |
58.3 (14/24) | 54.8 (17/31) |
Gram-negative | |
H. influenzae | |
76.2 (16/21) | 71.4 (20/28) |
K. pneumoniae | |
77.8 (14/18) | 58.3 (7/12) |
K. oxytoca | |
100.0 (6/6) | 100.0 (6/6) |
E. coli | |
33.3 (4/12) | 53.8 (7/13) |
MSSA=Methicillin-susceptible Staphylococcus aureus.
Clinical efficacy of TEFLARO in treating CABP due to MRSA has not been studied.
These hypothetical case studies present examples of types of patients who may benefit from TEFLARO.
Please also see full Prescribing Information.
Please also see full Prescribing Information.